VolitionRx’s (VNRX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a $3.00 target price on the stock.

A number of other research analysts also recently weighed in on the stock. HC Wainwright decreased their price objective on shares of VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a research report on Monday, November 17th. Maxim Group cut VolitionRx from a “buy” rating to a “hold” rating in a report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, VolitionRx presently has an average rating of “Buy” and an average target price of $2.50.

VolitionRx Trading Down 8.3%

Shares of VNRX stock opened at $0.29 on Wednesday. VolitionRx has a twelve month low of $0.22 and a twelve month high of $0.94. The stock has a 50 day moving average of $0.29 and a 200 day moving average of $0.49. The stock has a market cap of $35.80 million, a P/E ratio of -0.81 and a beta of 1.23.

Institutional Trading of VolitionRx

Several large investors have recently bought and sold shares of VNRX. Blair William & Co. IL purchased a new position in VolitionRx in the 2nd quarter worth approximately $30,000. Virtu Financial LLC acquired a new stake in shares of VolitionRx in the third quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of VolitionRx in the second quarter valued at approximately $52,000. Silverberg Bernstein Capital Management LLC lifted its position in VolitionRx by 15.6% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock worth $157,000 after buying an additional 31,300 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in VolitionRx by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after buying an additional 135,775 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.